Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NonInterventional, Multicenter, Prospective, European Study to Describe the Effectiveness of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients According to SmPC Regardless of Previous Use of an Antiangiogenic Drug

NCT02825420 is registered in ClinicalTrials.gov with PharmaMar as lead sponsor.

NCT NCT02825420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02825420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NonInterventional, Multicenter, Prospective, European Study to Describe the Effectiveness of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients According to SmPC Regardless of Previous Use of an Antiangiogenic Drug
Lead sponsor
PharmaMar
Phase
Observational
Overall status
Completed
Start date
July 28, 2015
Completion date
September 18, 2019
Enrollment
220 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed ovarian cancer